LAS VEGAS, NV / ACCESSWIRE / May 12, 2015 / PINKSHEETS: VRCI Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions is pleased to announce the appointment of David Alexander, CA as its new CFO, effective immediately. David graduated with BComm in Finance from the University of British Columbia. He has managed the rapid growth of several early stage and startup companies. As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, and listed it on Nasdaq. Arakis was subsequently sold to Talisman Energy Inc. He was also CFO of Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical Research and Development Company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran subsequently, became into Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company (Nasdaq:CRME).
According to David, "Verde Science possesses several elements for success in the pharmaceutical research, development and commercialization arena. I am pleased to be part of the team that Harp has assembled and to assist in financing and managing the significant growth that the company envisions."
CEO, Harp Sangha commented, "I am delighted to have David join Verde Science at this time in our development. He is exactly what Verde Science needs – a growth oriented CFO. His success in managing and accelerating the growth of early stage companies, specifically in the pharmaceutical sector should prove to be invaluable."
